FDA Approves Bempedoic Acid, Ezetimibe Combination Therapy for LDL-C Lowering
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.
Familial Hypercholesterolemia
Effects of Hypertriglyceridemia on Lipoprotein Function in Familial Combined Hyperlipidemia
Patients with familial combined hyperlipidemia may have more severe pro-atherogenic changes in the presence vs absence of hypertriglyceridemia.
Genetic Etiology of Hypercholesterolemia May Affect CVD Risk
Individuals with hypercholesterolemia without an identifiable genetic cause may be at a relatively lower risk for CVD than those with monogenic or polygenic etiologies.
Public Policy Recommendations Updated for Familial Hypercholesterolemia
Updated recommendations are presented for reducing the clinical and public health burden of familial hypercholesterolemia.
Statins in Childhood Aid Familial Hypercholesterolemia Outcomes
Initiation of statin therapy during childhood in patients with familial hypercholesterolemia slows the progression of carotid intima-media thickness and reduces the risk for cardiovascular disease over 20 years.
More Aggressive Therapy Needed for Many Patients With Familial Hypercholesterolemia
Even with care in specialty clinics, LDL-C persists above target levels in more than half of patients with familial hypercholesterolemia.
Studies Show Inclisiran Benefits Patients With HeFH, ASCVD, and Elevated LDL-C
Full detailed data will be presented at the AHA Scientific Sessions in Philadelphia in November 2019.
Lomitapide Reduces LDL-C Levels in Homozygous Familial Hypercholesterolemia
Lomitapide reduced low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, with some patients reaching recommended targets.
Evinacumab Effective in Homozygous Familial Hypercholesterolemia Trial
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Monogenic Familial Hypercholesterolemia Increases Premature CVD Risk
Investigators sought to determine whether a monogenic cause substantially increases the risk for premature cardiovascular disease in patients with familial hypercholesterolemia.
Next post in Cardiovascular and Metabolic Disorders
